anti-CD16/anti‐GD2 bispecific NK-cell engager (New York Medical College/Altor Bioscience)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD16/anti‐GD2 bispecific NK-cell engager (New York Medical College/Altor Bioscience)
Drug Alias Nameanti-CD16/anti‐GD2 bispecific immune-cell engager (New York Medical College/Altor Bioscience)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor III agonists
TargetsLow affinity immunoglobulin gamma Fc region receptor III
Therapy Area/IndicationsNeuroblastomaSarcoma, Ewing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNew York Medical College
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNew York Medical CollegeAltor Bioscience Corp
Active IndicationsN/A
Inactive IndicationsNeuroblastomaSarcoma, Ewing

Other Information

ATC CodeN/A
Related LinksN/A